Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-label, Dose Escalation and Extension Study of Intravesical Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

NCT06816017 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT06816017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06816017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-label, Dose Escalation and Extension Study of Intravesical Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Withdrawn
Start date
June 15, 2025
Completion date
October 31, 2030
Enrollment
0 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle invasive bladder cancer